Last reviewed · How we verify
aspirin + celecoxib
This combination inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation through dual NSAID action.
This combination inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation through dual NSAID action. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain conditions.
At a glance
| Generic name | aspirin + celecoxib |
|---|---|
| Also known as | aspirin : Keun-Hwa Phamaceutical, clopidogrel : sanofi-aventis, celecoxib : Pfizer |
| Sponsor | Seoul National University Hospital |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) combination |
| Target | COX-1 and COX-2 enzymes |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits both COX-1 and COX-2 enzymes, while celecoxib selectively inhibits COX-2. Together they provide complementary anti-inflammatory, analgesic, and antipyretic effects by suppressing prostaglandin production. This combination approach may enhance therapeutic efficacy, though it carries increased gastrointestinal and cardiovascular risk compared to monotherapy.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Cardiovascular events
- Renal impairment
Key clinical trials
- Timed Aspirin Chronobiome Study (EARLY_PHASE1)
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Minimal Opioid Use After Total Hip Replacement (THR) (PHASE4)
- Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS (PHASE4)
- RACIN in Patients With Advanced TIL-negative Solid Tumors (PHASE1)
- Pain Treatment With Combinations of NSAIDs (NA)
- PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer (PHASE2)
- Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin + celecoxib CI brief — competitive landscape report
- aspirin + celecoxib updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI